Immune checkpoint inhibitors are becoming more commonly used for many forms of malignancy. With this class of medications being more heavily used, there has been an associated rise in medication-induced autoimmune hepatitis. This case involves a 35-year-old woman being treated with nivolumab/ipilimumab for renal cell carcinoma who developed a steroid-refractory autoimmune hepatitis.
Keywords: autoimmune hepatitis; check point inhibitor; chemotherapy; drug induced liver injury; drug-induced autoimmune hepatitis; hepatitis; ipilimumab; nivolumab; renal cell carcinoma; steroid refractory; tocilizumab.
© 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.